The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Markers of Adenocarcinoma Characteristic of the Site of Origin: Development of a Diagnostic Algorithm
Open accessAbstract
Purpose: Patients with metastatic adenocarcinoma of unknown origin are a common clinical problem. Knowledge of the primary site is important for their management, but histologically, such tumors appear similar. Better diagnostic markers are needed to enable the assignment of metastases to likely sites of origin on pathologic samples. Experimental Design: Expression profiling of 27 candidate markers was done using tissue microarrays and immunohistochemistry. In the first (training) round, we studied 352 primary adenocarcinomas, from seven main sites (breast, colon, lung, ovary, pancreas, prostate and stomach) and their differential diagnoses. Data were analyzed in Microsoft Access and the Rosetta system, and used to develop a classification scheme. In the second (validation) round, we studied 100 primary adenocarcinomas and 30 paired metastases. Results: In the first round, we generated expression profiles for all 27 candidate markers in each of the seven main primary sites. Data analysis led to a simplified diagnostic panel and decision tree containing 10 markers only: CA125, CDX2, cytokeratins 7 and 20, estrogen receptor, gross cystic disease fluid protein 15, lysozyme, mesothelin, prostate-specific antigen, and thyroid transcription factor 1. Applying the panel and tree to the original data provided correct classification in 88%. The 10 markers and diagnostic algorithm were then tested in a second, independent, set of primary and metastatic tumors and again 88% were correctly classified. Conclusions: This classification scheme should enable better prediction on biopsy material of the primary site in patients with metastatic adenocarcinoma of unknown origin, leading to improved management and therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue microarrays for high-throughput molecular profiling of tumor specimens
Kononen, J., Bubendorf, L., Kallionimeni, A., Bärlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,099
Cytokeratin 7 and Cytokeratin 20 Expression in Epithelial Neoplasms: A Survey of 435 Cases
Chu, P., Wu, E., & Weiss, L. M. (2000) · Modern Pathology · doi:10.1038/modpathol.3880175 · Cited by 1,024
Validation of Tissue Microarray Technology in Breast Carcinoma
Camp, R. L., Charette, L. A., & Rimm, D. L. (2000) · Laboratory Investigation · doi:10.1038/labinvest.3780204 · Cited by 799
Diagnostic and therapeutic management of cancer of an unknown primary
Pavlidis, N., Briasoulis, E., Hainsworth, J., & Greco, F. A. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00547-1 · Cited by 597
Molecular profiling of human cancer
Liotta, L., & Petricoin, E. (2000) · Nature Reviews Genetics · doi:10.1038/35049567 · Cited by 446
Application of Mesothelin Immunostaining in Tumor Diagnosis
Ordóñez, N. G. (2003) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200311000-00003 · Cited by 382
Moskaluk, C. A., Zhang, H., Powell, S. M., Cerilli, L. A., Hampton, G. M., & Frierson, H. F. (2003) · Modern Pathology · doi:10.1097/01.mp.0000086073.92773.55 · Cited by 291
Cytokeratins 20 and 7 as biomarkers
Tot, T. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00008-4 · Cited by 285
Diagnostic strategies for unknown primary cancer
Varadhachary, G. R., Abbruzzese, J. L., & Lenzi, R. (2004) · Cancer · doi:10.1002/cncr.20202 · Cited by 266
Frierson, H. F., Moskaluk, C. A., Powell, S. M., Zhang, H., Cerilli, L. A., Stoler, M. H., Cathro, H., & Hampton, G. M. (2003) · Human Pathology · doi:10.1016/s0046-8177(03)00177-1 · Cited by 171
Cited by
Bussani, R., De-Giorgio, F., Abbate, A., & Silvestri, F. (2007) · Journal of Clinical Pathology · doi:10.1136/jcp.2005.035105 · Cited by 642
Cancer of Unknown Primary Site
Varadhachary, G. R., & Raber, M. N. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1303917 · Cited by 261
SATB2 in Combination With Cytokeratin 20 Identifies Over 95% of all Colorectal Carcinomas
Magnusson, K., de Wit, M., Brennan, D. J., Johnson, L. B., McGee, S. F., Lundberg, E., Naicker, K., Klinger, R., Kampf, C., Asplund, A., et al. (2011) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31821c3dae · Cited by 256
Abraham, J., Heimberger, A. B., Marshall, J., Heath, E., Drabick, J., Helmstetter, A., Xiu, J., Magee, D., Stafford, P., Nabhan, C., et al. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101016 · Cited by 47
Metadata
- Authors
- Dennis, J. L., Hvidsten, T. R., Wit, E. C., Komorowski, J., Bell, A. K., Downie, I., Mooney, J., Verbeke, C., Bellamy, C., Keith, W. N., & Oien, K. A.
- Venue
- Clinical Cancer Research
- Published
- 2005-05-15
- Volume
- 11
- Issue
- 10
- Pages
- 3766-3772
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2150760649
- Cited by
- 320
- References
- 17
- FWCI
- 9.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Markers of Adenocarcinoma Characteristic of the Site of Origin: Development of a Diagnostic Algorithm. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-04-2236
- The paper
- Dennis, J. L., Hvidsten, T. R., Wit, E. C., Komorowski, J., Bell, A. K., Downie, I., Mooney, J., Verbeke, C., Bellamy, C., Keith, W. N., & Oien, K. A. (2005). Markers of Adenocarcinoma Characteristic of the Site of Origin: Development of a Diagnostic Algorithm. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-04-2236
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.